Download PDF
Thromb Haemost 2008; 99(01): 2-3
DOI: 10.1160/TH07-12-0713
Editorial Focus
Schattauer GmbH

Fondaparinux versus direct thrombin inhibitor therapy for the management of heparin-induced thrombocytopenia (HIT) – Bridging the River Coumarin

Theodore E Warkentin
1   Department of Pathology and Molecular Medicine, and Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada
› Author AffiliationsFinancial support: Some of the studies described in this editorial were supported by the Heart and Stroke Foundation of Ontario (T5207, T6157 [TEW]).
Further Information

Publication History

Received: 03 December 2007

Accepted after major revision: 03 December 2007

Publication Date:
24 November 2017 (online)

   Permissions and Reprints

 

 

  • References

  • 1 Bradner JE, Eikelboom JW. Emerging anticoagulants and heparin-induced thrombocytopenia: indirect and direct factor Xa inhibitors and oral thrombin inhibitors. Warkentin TE, Greinacher A. Heparin- Induced Thrombocytopenia. 4th ed. New York: Informa Healthcare USA, Inc.; 2007: 441-461.
    Google Scholar
  • 2 Warkentin TE, Cook RJ, Marder VJ. et al. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood 2005; 106: 3791-3796.
    CrossrefPubMedGoogle Scholar
  • 3 Warkentin TE, Maurer BT, Aster RH. Heparin-induced thrombocytopenia associated with fondaparinux. N Engl J Med 2007; 356: 2653-2654.
    CrossrefPubMedGoogle Scholar
  • 4 Efird LE, Kockler DR. Fondaparinux for thromboembolic treatment and prophylaxis of heparin-induced thrombocytopenia. Pharmacotherapy 2006; 40: 1383-1387.
    CrossrefPubMedGoogle Scholar
  • 5 Smythe MA, Warkentin TE, Stephens JL. et al. Venous limb gangrene during overlapping therapy with warfarin and a direct thrombin inhibitor for immune heparin-induced thrombocytopenia. Am J Hematol 2002; 71: 50-52.
    CrossrefPubMedGoogle Scholar
  • 6 Warkentin TE. Should vitamin K be administered when HIT is diagnosed after administration of coumarin?. J Thromb Haemost 2006; 4: 894-896.
    CrossrefPubMedGoogle Scholar
  • 7 Lobo B, Finch C, Howard A. et al. Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia. Thromb Haemost 2008; 99: 208-214.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Warkentin TE, Greinacher A, Craven S. et al. Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation. Thromb Haemost 2005; 94: 958-964.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Lo GK, Sigouin CS, Warkentin TE. What is the potential for overdiagnosis of heparin-induced thrombocytopenia?. Am J Hematol 2007; 82: 1037-1043.
    CrossrefPubMedGoogle Scholar
  • 10 Lubenow N, Warkentin TE, Greinacher A. et al. Results of a systematic evaluation of treatment outcomes for heparin-induced thrombocytopenia in patients receiving danaparoid, ancrod, and/or coumarin explain the rapid shift in clinical practice during the 1990s. Thromb Res 2006; 117: 507-515.
    CrossrefPubMedGoogle Scholar